Open Access
J Brachial Plex Peripher Nerve Inj 2010; 05(01): e124-e130
DOI: 10.1186/1749-7221-5-11
Methodology
Milani et al; licensee BioMed Central Ltd.

Progesterone - new therapy in mild carpal tunnel syndrome? Study design of a randomized clinical trial for local therapy[*]

Paolo Milani
1   Dept. Neurological, Neurosurgical and Behavioural Sciences, Neurophysiology Clinic Section, University of Siena, Siena, Italy
2   Service de Physiologie Explorations Fonctionnelles, Hôpital Lariboisière, AP-HP, 2 rue Ambroise-Paré, 75010 Paris, France
3   Université Paris 7 Denis-Diderot, 2 rue Ambroise-Paré, 75010 Paris, France
,
Mauro Mondelli
4   EMG Service, Local Health Unit 7, Siena, Italy
,
Federica Ginanneschi
1   Dept. Neurological, Neurosurgical and Behavioural Sciences, Neurophysiology Clinic Section, University of Siena, Siena, Italy
,
Riccardo Mazzocchio
1   Dept. Neurological, Neurosurgical and Behavioural Sciences, Neurophysiology Clinic Section, University of Siena, Siena, Italy
,
Alessandro Rossi
1   Dept. Neurological, Neurosurgical and Behavioural Sciences, Neurophysiology Clinic Section, University of Siena, Siena, Italy
› Author Affiliations

Subject Editor:
Further Information

Publication History

15 December 2009

26 April 2010

Publication Date:
19 September 2014 (online)

Preview

Abstract

Background Local corticosteroid injection for carpal tunnel syndrome (CTS) provides greater clinical improvement in symptoms one month after injection compared to placebo but significant symptom relief beyond one month has not been demonstrated and the relapse of symptoms is possible.

Neuroprotection and myelin repair actions of the progesterone was demonstrated in vivo and in vitro study.

We report the design of a randomized controlled trial for the local injection of cortisone versus progesterone in “mild” idiopathic CTS.

Methods Sixty women with age between 18 and 60 years affected by “mild” idiopathic CTS, diagnosed on the basis of clinical and electrodiagnostic tests, will be enrolled in one centre. The clinical, electrophysiological and ultasonographic findings of the patients will be evaluate at baseline, 1, 6 and 12 months after injection.

The major outcome of this study is to determine whether locally-injected progesterone may be more beneficial than cortisone in CTS at clinical levels, tested with symptoms severity self-administered Boston Questionnaire and with visual analogue pain scale.

Secondary outcome measures are: duration of experimental therapy; improvement of electrodiagnostic and ultrasonographic anomalies at various follow-up; comparison of the beneficial and harmful effects of the cortisone versus progesterone.

Conclusion We have designed a randomized controlled study to show the clinical effectiveness of local progesterone in the most frequent human focal peripheral mononeuropathy and to demonstrate the neuroprotective effects of the progesterone at the level of the peripheral nervous system in humans.

*This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.